QUÉBEC, March 30, 2026 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on March 27, 2026 (the "Meeting") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
